Header Logo

Donald M. Jensen

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentInternal Medicine, Division of Digestive Diseases and Nutrition
Address
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 7402549621.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Jensen DM, Rzepczynski A, Jensen EE, Reau N. The American Association for the Study of Liver Diseases: A history of the first 10 years and its presidents. Hepatology. 2022 09; 76(3):854-859. PMID: 35416324.
      Citations:    
    2. Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther. 2019; 13:2565-2577. PMID: 31534310.
      Citations:    
    3. Mikolajczyk AE, Farnan JM, McConville JF, Jensen DM, Reddy KG, Te HS, Reau N, Aronsohn AI. Novel educational interventions in residency increase knowledge of chronic liver disease and career interest in hepatology. Hepatology. 2016 12; 64(6):2210-2218. PMID: 27506929.
      Citations:    
    4. Jensen DM, Sebhatu P, Reau NS. Generic medications for hepatitis C. Liver Int. 2016 07; 36(7):925-8. PMID: 27306302.
      Citations:    
    5. Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Yoshida EM, Moreno C, Ouzan D, Wright M, Morano LE, Buynak R, Bourli?re M, Hassanein T, Nishiguchi S, Kao JH, Omata M, Paik SW, Wong DK, Tam E, Kaita K, Feinman SV, Stern JO, Scherer J, Quinson AM, Voss F, Gallivan JP, B?cher WO, Ferenci P. Faldaprevir, pegylated interferon, and ribavirin for treatment-na?ve HCV genotype-1: pooled analysis of two phase 3 trials. Ann Hepatol. 2016 May-Jun; 15(3):333-49. PMID: 27049487.
      Citations:    
    6. Kataria Y, Deaton RJ, Enk E, Jin M, Petrauskaite M, Dong L, Goldenberg JR, Cotler SJ, Jensen DM, van Breemen RB, Gann PH. Retinoid and carotenoid status in serum and liver among patients at high-risk for liver cancer. BMC Gastroenterol. 2016 Feb 29; 16:30. PMID: 26927700.
      Citations:    
    7. Kao JH, Jensen DM, Manns MP, Jacobson I, Kumada H, Toyota J, Heo J, Yoffe B, Sievert W, Bessone F, Peng CY, Roberts SK, Lee YJ, Bhore R, Mendez P, Hughes E, Noviello S. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. Liver Int. 2016 07; 36(7):954-62. PMID: 26683763.
      Citations:    
    8. Jensen DM, Brunda M, Elston R, Gane EJ, George J, Glavini K, Hammond JM, Le Pogam S, N?jera I, Passe S, Piekarska A, Rodriguez I, Zeuzem S, Chu T. Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. Liver Int. 2016 Apr; 36(4):505-14. PMID: 26519669.
      Citations:    
    9. Mikolajczyk AE, Aronsohn AA, McConville JF, Jensen DM, Farnan JM. A call to action: The need for hepatology-focused educational interventions in Internal Medicine Residency training. Hepatology. 2015 Aug; 62(2):655-6. PMID: 25363161.
      Citations:    
    10. Welch NM, Jensen DM. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C. Liver Int. 2015 Jan; 35 Suppl 1:11-7. PMID: 25529082.
      Citations:    
    11. Feld JJ, Jacobson IM, Jensen DM, Foster GR, Pol S, Tam E, Jablkowski M, Berak H, Vierling JM, Yoshida EM, Perez-Gomez HR, Scalori A, Hooper GJ, Tavel JA, Navarro MT, Shahdad S, Kulkarni R, Le Pogam S, N?jera I, Eng S, Lim CY, Shulman NS, Yetzer ES. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015 Feb; 62(2):294-302. PMID: 25239078.
      Citations:    
    12. Petty LA, Steinbeck JL, Pursell K, Jensen DM. Human immunodeficiency virus and coinfection with hepatitis B and C. Infect Dis Clin North Am. 2014 Sep; 28(3):477-99. PMID: 25151567.
      Citations:    
    13. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourli?re M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24; 370(17):1604-14. PMID: 24720679.
      Citations:    
    14. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology. 2014 Apr; 59(4):1246-9. PMID: 24493069.
      Citations:    
    15. Jensen DM, Nathanson MH. Faster than a speeding bullet. Hepatology. 2014 Mar; 59(3):741-2. PMID: 24497126.
      Citations:    
    16. Marcellin P, Craxi A, Brandao-Mello CE, Di Bisceglie AM, Andreone P, Freilich B, Rajender Reddy K, Olveira Mart?n A, Teuber G, Messinger D, Hooper G, Wat C, Tatsch F, Jensen DM. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment. J Clin Gastroenterol. 2013 Oct; 47(9):786-93. PMID: 23442834.
      Citations:    
    17. Fried MW, Jensen DM. The FDA, bridging data, and hepatitis C. Hepatology. 2013 Mar; 57(3):875-7. PMID: 23456679.
      Citations:    
    18. Dabbouseh NM, Jensen DM. Future therapies for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013 May; 10(5):268-76. PMID: 23419289.
      Citations:    
    19. Wedemeyer H, Jensen DM, Godofsky E, Mani N, Pawlotsky JM, Miller V. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology. 2012 Dec; 56(6):2398-403. PMID: 22707382.
      Citations:    
    20. Jenkins ET, Jensen DM. The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus. Infect Dis Clin North Am. 2012 Dec; 26(4):879-91. PMID: 23083821.
      Citations:    
    21. Nelson DR, Jensen DM, Sulkowski MS, Everson G, Fried MW, Gordon SC, Jacobson I, Reau NS, Sherman K, Terrault N, Thomas D. Hepatitis C virus: a critical appraisal of new approaches to therapy. Hepat Res Treat. 2012; 2012:138302. PMID: 23094146.
      Citations:    
    22. Marcellin P, Roberts SK, Reddy KR, Harrison SA, Jensen DM, Hadziyannis S, Diago M, Weltman M, Messinger D, Tatsch F, Rizzetto M. Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opin Drug Saf. 2012 Nov; 11(6):901-9. PMID: 22943161.
      Citations:    
    23. Te HS, Dasgupta KA, Cao D, Satoskar R, Mohanty SR, Reau N, Millis JM, Jensen DM. Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant. 2012 Nov-Dec; 26(6):826-32. PMID: 22554357.
      Citations:    
    24. Jensen DM, Pol S. IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late? Liver Int. 2012 Feb; 32 Suppl 1:74-8. PMID: 22212576.
      Citations:    
    25. Nelson DR, Zeuzem S, Andreone P, Ferenci P, Herring R, Jensen DM, Marcellin P, Pockros PJ, Rodr?guez-Torres M, Rossaro L, Rustgi VK, Sepe T, Sulkowski M, Thomason IR, Yoshida EM, Chan A, Hill G. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol. 2012 Jan-Feb; 11(1):15-31. PMID: 22166557.
      Citations:    
    26. Di Martino V, Richou C, Cervoni JP, Sanchez-Tapias JM, Jensen DM, Mangia A, Buti M, Sheppard F, Ferenci P, Th?venot T. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology. 2011 Sep 02; 54(3):789-800. PMID: 21674553.
      Citations:    
    27. Jensen DM. A new era of hepatitis C therapy begins. N Engl J Med. 2011 Mar 31; 364(13):1272-4. PMID: 21449791.
      Citations:    
    28. Jensen DM. Treatment duration for genotypes 2 and 3: still confusing after all these years. J Clin Gastroenterol. 2010 Sep; 44(8):527-8. PMID: 20628314.
      Citations:    
    29. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010 Feb; 14(1):1-21, vii. PMID: 20123436.
      Citations:    
    30. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brand?o-Mello CE, Reddy KR, Craxi A, Martin AO, Teuber G, Messinger D, Thommes JA, Tietz A. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med. 2009 Apr 21; 150(8):528-40. PMID: 19380853.
      Citations:    
    31. McGreal N, Jensen DM. Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure. Liver Int. 2009 Apr; 29(4):481-2. PMID: 19323778.
      Citations:    
    32. Jensen DM. Individualizing HCV Treatment with Peginterferon and Ribavirin: What needs to be Done? Therap Adv Gastroenterol. 2009 Jan; 2(1):5-10. PMID: 21180530.
      Citations:    
    33. Mohanty SR, Troy TN, Huo D, O'Brien BL, Jensen DM, Hart J. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol. 2009 Apr; 50(4):797-804. PMID: 19231016.
      Citations:    
    34. Fried MW, Jensen DM, Rodriguez-Torres M, Nyberg LM, Di Bisceglie AM, Morgan TR, Pockros PJ, Lin A, Cupelli L, Duff F, Wang K, Nelson DR. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology. 2008 Oct; 48(4):1033-43. PMID: 18697207.
      Citations:    
    35. Mishra P, DeVoss A, Pai R, Hart J, Jensen DM. Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report. Dig Dis Sci. 2009 Jun; 54(6):1369-72. PMID: 18770036.
      Citations:    
    36. Mishra P, Jensen DM. Hepatitis C: current and future therapies. Mt Sinai J Med. 2008 Aug; 75(4):405-14. PMID: 18729159.
      Citations:    
    37. Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008 Aug; 103(8):1981-8. PMID: 18796095.
      Citations:    
    38. Te HS, Anderson AS, Millis JM, Jeevanandam V, Jensen DM. Current state of combined heart-liver transplantation in the United States. J Heart Lung Transplant. 2008 Jul; 27(7):753-9. PMID: 18582805.
      Citations:    
    39. Martin P, Jensen DM. Ribavirin in the treatment of chronic hepatitis C. J Gastroenterol Hepatol. 2008 Jun; 23(6):844-55. PMID: 18565019.
      Citations:    
    40. Reau NS, Jensen DM. Vanishing bile duct syndrome. Clin Liver Dis. 2008 Feb; 12(1):203-17, x. PMID: 18242505.
      Citations:    
    41. Jensen DM, Ascione A. Future directions in therapy for chronic hepatitis C. Antivir Ther. 2008; 13 Suppl 1:31-6. PMID: 18432161.
      Citations:    
    42. Satoskar R, Jensen DM. Retreatment of chronic hepatitis C in previous non-responders and relapsers. Expert Opin Pharmacother. 2007 Oct; 8(15):2491-503. PMID: 17931085.
      Citations:    
    43. Sauk J, Jensen DM, Mohanty SR, Reau N, Reddy KG, Te HS. Lack of Efficacy of Pegylated Interferon Monotherapy for Hepatitis C in Patients With End-Stage Renal Disease on Dialysis. Gastroenterol Hepatol (N Y). 2006 Jul; 2(7):504-508. PMID: 28289353.
      Citations:    
    44. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006 May; 43(5):954-60. PMID: 16628671.
      Citations:    
    45. Jensen DM, Marcellin P. Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. Eur J Gastroenterol Hepatol. 2005 Sep; 17(9):899-904. PMID: 16093865.
      Citations:    
    46. Cohen SM, Gundlapalli S, Shah AR, Johnson TJ, Rechner JA, Jensen DM. The downstream financial effect of hepatology. Hepatology. 2005 May; 41(5):968-75. PMID: 15841443.
      Citations:    
    47. Cotler SJ, Kanji K, Keshavarzian A, Jensen DM, Jakate S. Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J Clin Gastroenterol. 2004 Oct; 38(9):801-4. PMID: 15365409.
      Citations:    
    48. Sotil EU, Jensen DM. Serum enzymes associated with cholestasis. Clin Liver Dis. 2004 Feb; 8(1):41-54, vi. PMID: 15062192.
      Citations:    
    49. Kaplan M, Gawrieh S, Cotler SJ, Jensen DM. Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics. Gastroenterology. 2003 Aug; 125(2):597-604. PMID: 12891562.
      Citations:    
    50. Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain VG, Sherman M, Feinman SV, Fried MW, Rasenack J, Sarrazin C, Jensen DM, Lin A, Hoffman JH, Sedarati F. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol. 2003 Jul; 39(1):106-11. PMID: 12821051.
      Citations:    
    51. Cotler SJ, Cotler S, Gambera M, Benedetti E, Jensen DM, Testa G. Adult living donor liver transplantation: perspectives from 100 liver transplant surgeons. Liver Transpl. 2003 Jun; 9(6):637-44. PMID: 12783411.
      Citations:    
    52. Cotler SJ, Morrissey MJ, Wiley TE, Layden TJ, Jensen DM. A pilot study of the combination of cyclosporin A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients. J Clin Gastroenterol. 2003 Apr; 36(4):352-5. PMID: 12642744.
      Citations:    
    53. Cotler SJ, Diaz G, Gundlapalli S, Jakate S, Chawla A, Mital D, Jensik S, Jensen DM. Characteristics of hepatitis C in renal transplant candidates. J Clin Gastroenterol. 2002 Aug; 35(2):191-5. PMID: 12172367.
      Citations:    
    Jensen's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (232)
    Explore
    _
    Co-Authors (4)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _